CDK4/6 inhibitors vs. weekly paclitaxel for ER+/HER2- advanced breast cancer with impending or established visceral crisis
In this retrospective study, patients with ER+/HER2- advanced breast cancer and impending or established visceral crisis had better outcomes when treated with a CDK4/6 inhibitor + endocrine therapy compared to weekly paclitaxel.
